MRSN

Mersana Therapeutics, Inc. (MRSN) ESG Analysis Analysis (2026)

Invetso Score: 4.5/10 — Balanced · Last Updated: 2026-09-01

Environmental

No material environmental disclosures or sustainability metrics were provided in the fresh data.

Capital intensity appears low in the TTM metrics, with capex-to-revenue at 0 and capex-to-operating cash flow at 0.

Social

No new workforce, customer, or community-related news was provided this month.

R&D remains a major operating priority, with research and development expense at 2.78x revenue in the TTM metrics.

Governance

No new governance, board, or compliance news was provided this month.

Financial leverage remains modest, with debt-to-assets at 3.66% and current ratio at 1.39, but profitability and cash-flow metrics remain weak.

Overall Score

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Mersana Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →